Advertisement

Effect of a single vaginal administration of levonorgestrel in Carraguard�� gel on the ovulatory process: a potential candidate for ���dual protection��� emergency contraception

      Abstract

      Objective

      The study was conducted to evaluate the effect of Carraguard vaginal gel containing 0.75 mg of levonorgestrel (CARRA/LNG gel) administered in a single dose at different stages of follicle development over subsequent follicle rupture and hormonal levels.

      Method

      Randomized, blinded, cross-over study comparing the effects of a single administration of CARRA/LNG gel or Carraguard (CARRA) gel. Twenty-four healthy women were enrolled in two centers. The gels were administered when the follicle had reached diameters of 12���14, 15���17 and ���18 mm in eight women each. Volunteers were followed for one treatment, one washout cycle and a second treatment cycle. Follicle rupture or nonrupture was assessed by transvaginal ultrasound. Luteinizing hormone, estradiol and progesterone levels were measured daily for 5 days following treatment, and three times per week until menses.

      Results

      No follicular rupture within the 5-day period following administration was observed in 74% and 30% of the CARRA/LNG and CARRA gel treatment cycles, respectively, while ovulation was documented in 4% and 61%, respectively. The overall proportion of cycles with lack of follicular rupture or ovulatory dysfunction (follicle rupture preceded by an inadequate LH surge) was 96% for CARRA/LNG and 39% in the CARRA gel cycles.

      Conclusion

      Single vaginal administration of 0.75 mg LNG in CARRA gel in the late follicular phase is effective for interfering with the ovulatory process.

      Keywords

      To read this article in full you will need to make a payment

      Purchase one-time access:

      Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
      One-time access price info
      • For academic or personal research use, select 'Academic and Personal'
      • For corporate R&D use, select 'Corporate R&D Professionals'

      Subscribe:

      Subscribe to Contraception
      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Institutional Access: Sign in to ScienceDirect

      References

        • Baba M.
        • Nakajima M.
        • Schols D.
        • Pauwels R.
        • Balzarini J.
        • De Clercq E.
        Pentosan polysulfate, a sulfated oligosaccharide, is a potent and selective anti-HIV agent in vitro.
        Antiviral Res. 1988; 9: 335-343
        • Pearce-Pratt R.
        • Phillips D.M.
        Sulfated polysaccharides inhibit lymphocyte-to-epithelial transmission of HIV-1.
        Biol Reprod. 1996; 54: 173-182
        • Zacharopoulos V.R.
        • Phillips D.M.
        Vaginal formulations of carrageenan protect mice from herpes simplex virus infection.
        Clin Diagn Lab Immunol. 1997; 4: 465-468
        • Jerse A.E.
        Experimental gonococcal genital tract infection and opacity protein expression in estradiol-treated mice.
        Infect Immun. 1999; 67: 5699-5708
        • Maguire R.
        • Bergman N.
        • Phillips D.M.
        Comparison of microbicides for efficacy in protecting mice against vaginal challenge with herpes simplex virus type 2, cytotoxicity, antibacterial properties, and sperm immobilization.
        Sex Transm Dis. 2001; 28: 259-265
        • Spencer S.E.
        • Valentin-Bon I.E.
        • Whaley K.
        • Jerse A.E.
        Inhibition of Neisseria gonorrhoeae genital tract infection by leading-candidate topical microbicides in a mouse model.
        J Infect Dis. 2004; 189: 410-419
        • Elias C.J.
        • Coggins C.
        • Alvarez F.
        • et al.
        Colposcopic evaluation of a vaginal gel formulation of iota-carrageenan.
        Contraception. 1997; 56: 387-389
        • Coggins C.
        • Blanchard K.
        • Alvarez F.
        • et al.
        Preliminary safety and acceptability of a carrageenan gel for possible use as a vaginal microbicide.
        Sex Transm Infect. 2000; 76: 480-483
        • Kilmarx P.H.
        • van de Wilgert J.H.
        • Chaikummao S.
        • et al.
        Safety and acceptability of the candidate microbicide Carraguard in Thai women: findings from a Phase II clinical trial.
        J Acquir Immune Defic Syndr. 2006; 43: 327-334
      1. Sitruk-Ware R, Brache V, Maguire R, et al. Pharmacokinetic study to compare the absorption and tolerability of two doses of levonorgestrel following single vaginal administration of levonorgestrel in Carraguard�� gel: a new formulation for ���dual protection��� contraception. Contraception 2007;75:454���60.

        • Wilcox A.J.
        • Weinberg C.R.
        • Baird D.D.
        Timing of sexual intercourse in relation to ovulation. Effects on the probability of conception, survival of the pregnancy and sex of the baby.
        N Engl J Med. 1995; 333: 1517-1521
        • Croxatto H.B.
        • Brache V.
        • Pavez M.
        • et al.
        Pituitary���ovarian function following the standard levonorgestrel emergency contraceptive dose or a single 0.75 mg dose given on the days preceding ovulation.
        Contraception. 2004; 70: 442-450
        • Massai R.
        • Forcelledo M.L.
        • Brache V.
        • et al.
        Does meloxicam increase the incidence of anovulation induced by single administration of levonorgestrel in emergency contraception? A pilot study.
        Hum Reprod. 2007; 22: 434-439
        • Johansson E.
        • Brache V.
        • Alvarez F.
        • et al.
        Pharmacokinetic study of different dosing regimens of levonorgestrel for emergency contraception in healthy women.
        Hum Reprod. 2002; 17: 1472-1476
        • Tremblay D.
        • Gainer E.
        • Ulmann A.
        The pharmacokinetics of 750 ��g levonorgestrel after administration of one single dose or two doses at 12- or 24-h interval.
        Contraception. 2001; 64: 327-331
        • Kook K.
        • Gabelnick H.
        • Duncan G.
        Pharmacokinetics of levonorgestrel 0.75 mg tablets.
        Contraception. 2002; 66: 73-76
        • Alvarez F.
        • Faundes A.
        • Johansson E.
        • Coutinho E.
        Blood levels of levonorgestrel in women following vaginal placement of contraceptive pills.
        Fertil Steril. 1983; 40: 120-123
        • Kives S.
        • Hahn P.
        • White E.
        • Stanczyk F.Z.
        • Reid R.
        Bioavailability of the Yuzpe and levonorgestrel regimens of emergency contraception: vaginal vs. oral administration.
        Contraception. 2005; 71: 197-201
        • Devoto L.
        • Fuentes A.
        • Palomino A.
        • et al.
        Pharmacokinetics and endometrial tissue levels of levonorgestrel alter administration of a single 1.5-mg dose by the oral and vaginal route.
        Fertil Steril. 2005; 84: 46-51
        • De Ziegler D.
        • Bulletti C.
        • De Monstier B.
        • Jaaskelainen A.S.
        The first uterine pass effect.
        Ann N Y Acad Sci. 1997; 828: 291-299
        • Roumen F.J.M.E.
        • Dieben T.O.M.
        Comparison of uterine concentrations of ethinyl estradiol and etonogestrel after use of a contraceptive vaginal ring and an oral contraceptive.
        Fertil Steril. 2006; 85: 57-62
        • Alexander N.J.
        • Baker E.
        • Kaptein M.
        • Karck U.
        • Miller L.
        • Zampaglione E.
        Why consider vaginal drug administration?.
        Fertil Steril. 2004; 82: 1-12
        • Von Hertzen H.
        • Piaggio G.
        • Ding J.
        • et al.
        Low dose mifepristone and two regimens of levonorgestrel for emergency contraception: a WHO multicentre randomised trial.
        Lancet. 2002; 360: 1803-1810
        • WHO Task Force on Postovulatory Methods of Fertility Regulation
        Efficacy and side effects of immediate postcoital levonorgestrel used repeatedly for contraception.
        Contraception. 2000; 61: 303-308
        • Dupont S.
        • Webber J.
        • Dass K.
        • Thornton S.
        Emergency contraceptive pill (ECP) and sexual risk behaviour.
        Int J STD AIDS. 2002; 13: 482-485
        • Fairhurst K.
        • Ziebland S.
        • Wyke S.
        • Seaman P.
        • Glasier A.
        Emergency contraception: why can't you give it away? Qualitative findings from an evaluation of advanced provision of emergency contraception.
        Contraception. 2004; 70: 25-29